Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Solid tumors require blood vessels for growth, and many new cancer therapies are directed against the tumor vasculature. The widely held view is that these antiangiogenic therapies should destroy the tumor vasculature, thereby depriving the tumor of oxygen and nutrients. Here, I review emerging evidence supporting an alternative hypothesis—that certain antiangiogenic agents can also transiently “normalize” the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and drug delivery. Drugs that induce vascular normalization can alleviate hypoxia and increase the efficacy of conventional therapies if both are carefully scheduled. A better understanding of the molecular and cellular underpinnings of vascular normalization may ultimately lead to more effective therapies not only for cancer but also for diseases with abnormal vasculature, as well as regenerative medicine, in which the goal is to create and maintain a functionally normal vasculature.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, the aberrant vasculature also restricts the access of recruited immune cells and anticancer therapeutics to tumors, resulting in reduced outcomes of cancer treatments.[ 18 ]”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [18]
In the citing paper
“Recently, research groups such as Jain, et al., have used the combination therapy of angiogenesis inhibitors along with chemotherapy [24], where the angiogenesis modulators are used to normalize the vasculature and improve the EPR effect–mediated drug delivery and efficacy of the cancer treatment.”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [24]
In the citing paper
“Because the tumor vasculature is immature (12) and lacks myogenic and autonomic regulation (5)”
In the citing paper
“Conversely, increased glycolytic rate and low perfusion/oxygenation contribute to intratumoral hypoxia and acidosis, which is alleviated with enhanced perfusion (12).”
In the citing paper
“A rationale for combining anti-VEGF therapy with chemotherapy is that anti-VEGF therapy caused tumor vasculature to normalize resulting in increased drug delivery to tumors [123].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [123]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citationAngiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Molecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,529
Self-citation
Research works printed but not linked: 12
- D. J. Hicklin L. M. Ellis J. Clin. Oncol. in press.
- J. Ma et al., Cancer Res.61, 5491 (2001).
- R. K. Jain, in Clinical Oncology, M. Abeloff et al., Eds. (Elsevier, New York, ed. 3, 2004), pp. 153–172.
- R. K. Jain, Clin. Cancer Res.5, 1605 (1999).
- C. G. Lee et al., Cancer Res.60, 5565 (2000).
- A. Kadambi et al., Cancer Res.61, 2404 (2001).
- M. Relf et al., Cancer Res.57, 963 (1997).
- Y. Izumi, L. Xu, E. di Tomaso, D. Fukumura, R. K. Jain, Nature416, 279 (2002).
- P. Perrotte et al., Clin. Cancer Res.5, 257 (1999).
- P. M. Gullino, in Biomedical Thermology, M. Gautherie, E. Albert, Eds. (A. R. Liss, New York, 1982), pp. 1–20.
- L. Flintoft, Nature Rev. Cancer4, 754 (2004).
- G. Griffon-Etienne, Y. Boucher, C. Brekken, H. D. Suit, R. K. Jain, Cancer Res.59, 3776 (1999).
Cited by
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
“Tumour vessels become abnormal in almost all aspects of their structure and functio”
BackgroundSelf-citationAccessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
“…angiogenic regulatory factors in their TME, or to pharmacological suppression of VEGF—evidence so-called ''vascular normalization ,'' in which vessels are less torturous, with better pericyte coverage, and improved and less erratic blood flow (De Bock et al., 2011; Goel et al., 2011; Jain, 2005).”
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Angiogenesis in life, disease and medicine
Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,482
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
“The abnormal organization and structure of the tumor vasculature leads to tortuous and leaky vessels and heterogeneous blood flow”
BackgroundSelf-citationTargeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
“Initially, hypoxia arises because of oxygen diffusion limitations in avascular primary tumours or their metastases, but the tumour microvasculature (induced in part as a response to this hypoxia) is highly abnorma”
BackgroundVEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
A view on drug resistance in cancer
Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Basic and Therapeutic Aspects of Angiogenesis
Potente, M., Gerhardt, H., & Carmeliet, P. (2011) · Cell · doi:10.1016/j.cell.2011.08.039 · Cited by 2,771
“Tumor Vessels Are Abnormal Tumor vessels display abnormal structure and function (Goel et al., 2011; Jain, 2005) with seemingly chaotic organization (Figure 7A).”
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
“These effects are expected to reduce tumor interstitial pressure and lead to enhanced uptake of cytotoxic agents and antibodies by the tumor (Jain, 2005; Willett et al., 2004).”
BackgroundAngiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
“An alternative hypothesis has been proposed by Jai”
BackgroundPericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and Promises
Armulik, A., Genové, G., & Betsholtz, C. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.07.001 · Cited by 2,653
“Tumor vessels thereby resemble the vessels of normal tissues, resulting in improved oxygen, drug, and nutrient delivery to the tumor (Jain, 2005).”
BackgroundHypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Imaging in the era of molecular oncology
Weissleder, R., & Pittet, M. J. (2008) · Nature · doi:10.1038/nature06917 · Cited by 2,364
“Interestingly, studies of tumour blood-vessel responses have shown that certain antiangiogenic agents transiently normalize the structure and function of tumour vasculature, instead of 'pruning' the vessels as was expecte”
BackgroundBone Tissue Engineering: Recent Advances and Challenges
Amini, A. R., Laurencin, C. T., & Nukavarapu, S. P. (2012) · Critical Reviews in Biomedical Engineering · doi:10.1615/critrevbiomedeng.v40.i5.10 · Cited by 2,336
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015) · Hypoxia · doi:10.2147/hp.s93413 · Cited by 2,066
“tumor; however, at the same time induce more aggresive and metastatic tumor phenotype.(71,72)”
BackgroundThe Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144
Eltzschig, H. K., & Carmeliet, P. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0910283 · Cited by 2,061
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Self-citationMolecular regulation of angiogenesis and lymphangiogenesis
Adams, R. H., & Alitalo, K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2183 · Cited by 2,019
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
Going deeper than microscopy: the optical imaging frontier in biology
Ntziachristos, V. (2010) · Nature Methods · doi:10.1038/nmeth.1483 · Cited by 1,896
“Together, confocal and 2P/MP microscopy have been used extensively for in vivo imaging of fluorescent proteins, probes or dyes to investigate structure, function and molecular events as they occur in unperturbed environment”
Pre-metastatic niches: organ-specific homes for metastases
Peinado, H., Zhang, H., Matei, I. R., Costa-Silva, B., Hoshino, A., Rodrigues, G., Psaila, B., Kaplan, R. N., Bromberg, J. F., Kang, Y., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.6 · Cited by 1,889
The Microenvironmental Landscape of Brain Tumors
Quail, D. F., & Joyce, J. A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.009 · Cited by 1,862
“Whether vascular normalization strategies in brain tumors will be more efficient than vascular depletion, for example through suboptimal dosing or scheduling of anti-angiogenic therapies that are already being applied clinically (Jain, 2005), remains an ongoing area of investigation.”
BackgroundThe tumor microenvironment at a glance
Balkwill, F. R., Capasso, M., & Hagemann, T. (2012) · Journal of Cell Science · doi:10.1242/jcs.116392 · Cited by 1,857
“The tumor vasculature is abnormal in almost every aspect of its structure and function (Jain, 2005).”
BackgroundBatchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
“Antiangiogenic therapy has the potential to normalize structurally and functionally abnormal tumor vasculature and improve the tumor microenvironment (Jain, 2001, 2005).”
BackgroundSelf-citationPrinciples and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675
Self-citationVEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Self-citationAntiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
“The normalized vessels would also resist shedding of cancer cells from the primary tumor, potentially decreasing metastases (Jain, 2005).”
InfluentialSelf-citationA DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo
Li, S., Jiang, Q., Liu, S., Zhang, Y., Tian, Y., Song, C., Wang, J., Zou, Y., Anderson, G. J., Han, J.-Y., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4071 · Cited by 1,471
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
Nishida, N., Yano, H., Nishida, T., Kamura, T., & Kojiro, M. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.213 · Cited by 1,434
Tumor angiogenesis and vascular normalization: alternative therapeutic targets
Viallard, C., & Larrivée, B. (2017) · Angiogenesis · doi:10.1007/s10456-017-9562-9 · Cited by 1,424
“It has been suggested that anti-angiogenic therapies could correct the structural and functional flaws of tumor blood vessels, a process referred to as ‘‘vascular normalization’’ [3, 4].”
BackgroundAwareness and current knowledge of breast cancer
Akram, M., Iqbal, M., Daniyal, M., & Khan, A. U. (2017) · Biological Research · doi:10.1186/s40659-017-0140-9 · Cited by 1,406
“Tumor cells get their nutrients and oxygen supply by angiogenesis [69].”
BackgroundJain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., & Batchelor, T. T. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2175 · Cited by 1,405
Self-citationRole of tumor microenvironment in tumorigenesis
Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., Gong, Z., Zhang, S., Zhou, J., Cao, K., et al. (2017) · Journal of Cancer · doi:10.7150/jca.17648 · Cited by 1,404
Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor
Bao, S., Wu, Q., Sathornsumetee, S., Hao, Y., Li, Z., Hjelmeland, A. B., Shi, Q., McLendon, R. E., Bigner, D. D., & Rich, J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1010 · Cited by 1,345
“Jain (19) has established vascular ‘‘normalization’’ as a potential key response to antiangiogenic therapies, in addition to the vascular pruning caused through targeting angiogenesis.”
BackgroundAngiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
“6).(370,371) Vascular normalization means that the disordered condition of tumor angiogenesis can be back to the normal state through measurable antiangiogenic agents.”
BackgroundBlock copolymer micelles in nanomedicine applications
Cabral, H., Miyata, K., Osada, K., & Kataoka, K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00199 · Cited by 1,309
Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.015 · Cited by 1,288
The role of nitric oxide in tumour progression
Fukumura, D., Kashiwagi, S., & Jain, R. K. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1910 · Cited by 1,259
Self-citationNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
“We had hypothesized that the normalized tumor vasculature may also inhibit the shedding of cancer cells into the circulation—a prerequisite for metastasis.(3) In an elegant study, Carmeliet et al(118) have now demonstrated this in mice.”
BackgroundSelf-citationTargeting Tumor Microenvironment for Cancer Therapy
Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040840 · Cited by 1,187
“Concerning the therapeutic outcome of such drugs, although they showed to improve patient survival, it has not been as great as expected, mostly related to the fact that patients stop responding or do not respond at all to these therapies, or even due to the side effects, for instance, the increased risk of arterial t…”
BackgroundInnovative Strategies for Hypoxic‐Tumor Photodynamic Therapy
Li, X., Kwon, N., Guo, T., Liu, Z., & Yoon, J. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201805138 · Cited by 1,175
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302529 · Cited by 1,120
“Indeed, the IFP reduction associated with vascular endothelial growth factor (VEGF) inhibitors is likely central to their clinically beneficial synergism with cytotoxic agents.(14) Hyaluronan (HA) is a non-sulphated glycosaminoglycan present in the extracellular matrix, composed of N-acetylglucosamine/glucuronic acid…”
Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
Nakamura, Y., Mochida, A., Choyke, P. L., & Kobayashi, H. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00437 · Cited by 1,101
Chauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Self-citationHuang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099
“Our previous reports indicated that antiangiogenic treatment could normalize tumor vessels as early as 2 d posttreatment (4, 19).”
BackgroundSelf-citationGenin, M., Clement, F., Fattaccioli, A., Raes, M., & Michiels, C. (2015) · BMC Cancer · doi:10.1186/s12885-015-1546-9 · Cited by 1,090
“[40] showed that when primary macrophages were incubated in direct co-culture with MCF-7 cells, they produced TNF-α that induced MCF-7 cell apoptosis.”
BackgroundThe Role of Mechanical Forces in Tumor Growth and Therapy
Jain, R. K., Martin, J. D., & Stylianopoulos, T. (2014) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-105259 · Cited by 1,044
“g VEGF, PDGF), which induce angiogenesis, are over-expressed in order to recruit endothelial cells to form new vessels (61, 62).”
Self-citationRational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization
Sun, Q., Zhou, Z., Qiu, N., & Shen, Y. (2017) · Advanced Materials · doi:10.1002/adma.201606628 · Cited by 1,058
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
Self-citationTen years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
“…VEGFA inhibition results in the apoptosis of endothelial cells that are not covered by pericytes and reduces the abnormal tortuosity and hyperpermeability of the tumour vasculature (‘normalization’), thus reducing tumour interstitial pressure and enhancing the delivery of cytotoxic agents 76,77 .”
BackgroundChen, Q., Feng, L., Liu, J., Zhu, W., Dong, Z., Wu, Y., & Liu, Z. (2016) · Advanced Materials · doi:10.1002/adma.201601902 · Cited by 1,034
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
Noguera-Troise, I., Daly, C., Papadopoulos, N. J., Coetzee, S., Boland, P., Gale, N. W., Chieh Lin, H., Yancopoulos, G. D., & Thurston, G. (2006) · Nature · doi:10.1038/nature05355 · Cited by 1,032
Wu, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080771 · Cited by 1,030
“Since the tumor vascular formation is mainly attributed to the effects of vascular endothelial growth factor (VEGF), the application of VEGF antibodies antagonizes the effect of VEGF and temporarily normalizes tumor vasculature [35].”
BackgroundHolmes, K., Roberts, O. L., Thomas, A. M., & Cross, M. J. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.05.013 · Cited by 1,020
TUMOR STROMA AND REGULATION OF CANCER DEVELOPMENT
Tlsty, T. D., & Coussens, L. M. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100224 · Cited by 987
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C., Petruzzelli, L., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.17 · Cited by 953
Pancreatic cancer stroma: an update on therapeutic targeting strategies
Hosein, A. N., Brekken, R. A., & Maitra, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0300-1 · Cited by 950
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors
Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., Smith, B. L., Ferrone, C. R., Hornicek, F. J., Boucher, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213353109 · Cited by 943
“Specifically, the decreased vascular permeability would decrease IFP and increase blood flow in previously static blood vessels, thereby increasing drug delivery and treatment efficacy of a number of therapies (1, 21, 22).”
BackgroundInfluentialSelf-citationPathophysiological consequences of VEGF-induced vascular permeability
Weis, S. M., & Cheresh, D. A. (2005) · Nature · doi:10.1038/nature03987 · Cited by 909
Metabolic Interactions in the Tumor Microenvironment
Lyssiotis, C. A., & Kimmelman, A. C. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.06.003 · Cited by 853
“Deregulated proliferation and growth factor release further influences blood vessel development, which is characterized by leaky vessels that inefficiently deliver nutrients and remove waste products of cellular metabolism, like lactate [17, 18].”
BackgroundNanomedicine in cancer therapy
Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01536-y · Cited by 878
“Once solid tumors grow to a diameter of 1–2mm, normal blood vessels present in the vicinity are no longer adequate to support their further proliferation, intratumoral angiogenesis is, therefore, mandatory for these tumors.(49,50) The newly formed tumor capillaries and blood vessels are structurally and functionally a…”
BackgroundQian, X., Zheng, Y., & Chen, Y. (2016) · Advanced Materials · doi:10.1002/adma.201602012 · Cited by 882
Nia, H. T., Munn, L. L., & Jain, R. K. (2020) · Science · doi:10.1126/science.aaz0868 · Cited by 855
Self-citationClaesson‐Welsh, L., & Welsh, M. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12019 · Cited by 868
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
“Driven by the high production of angiogenic factors, including VEGF, the tumor vasculature develops rapidly and accumulates structural abnormalities such as tortuosity, dilation, and hyperpermeability (Jain, 2005).”
BackgroundKalyane, D., Raval, N., Maheshwari, R., Tambe, V., Kalia, K., & Tekade, R. K. (2019) · Materials Science and Engineering: C · doi:10.1016/j.msec.2019.01.066 · Cited by 849
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
Emerging trends and new developments in regenerative medicine: a scientometric update (2000 – 2014)
Chen, C., Dubin, R., & Kim, M. C. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.920813 · Cited by 837
“2 2009 2012 5 Jain (2005) SCIENCE, V307, P58 [44] 203.”
Chemical Design and Synthesis of Functionalized Probes for Imaging and Treating Tumor Hypoxia
Liu, J.-N., Bu, W., & Shi, J. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00525 · Cited by 838
Nitric oxide signaling in health and disease
Lundberg, J. O., & Weitzberg, E. (2022) · Cell · doi:10.1016/j.cell.2022.06.010 · Cited by 826
Nichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820
“In line with this concept, antiangiogenic therapy normalizes tumor blood vessels, albeit transiently, resulting in better blood and oxygen flow and possibly alsomore efficient T cell extravasation from the blood into the tumor (56, 57).”
BackgroundStrategies for advancing cancer nanomedicine
Chauhan, V. P., & Jain, R. K. (2013) · Nature Materials · doi:10.1038/nmat3792 · Cited by 812
Self-citationRapid vascular regrowth in tumors after reversal of VEGF inhibition
Mancuso, M. R., Davis, R., Norberg, S. M., O'Brien, S., Sennino, B., Nakahara, T., Yao, V. J., Inai, T., Brooks, P., Freimark, B., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24612 · Cited by 809
Mazzone, M., Dettori, D., Leite de Oliveira, R., Loges, S., Schmidt, T., Jonckx, B., Tian, Y.-M., Lanahan, A. A., Pollard, P., Ruiz de Almodovar, C., et al. (2009) · Cell · doi:10.1016/j.cell.2009.01.020 · Cited by 812
“By contrast, tumor angiogenesis is often ''nonproductive'' as vessel abnormalization impairs oxygen supply (Jain, 2005).”
InfluentialEngineering vascularized tissue
Jain, R. K., Au, P., Tam, J., Duda, D. G., & Fukumura, D. (2005) · Nature Biotechnology · doi:10.1038/nbt0705-821 · Cited by 808
Self-citationStromal Fibroblasts in Cancer: A Novel Tumor-Promoting Cell Type
Orimo, A., & Weinberg, R. A. (2006) · Cell Cycle · doi:10.4161/cc.5.15.3112 · Cited by 799
Intraventricular Hemorrhage in Premature Infants: Mechanism of Disease
Ballabh, P. (2010) · Pediatric Research · doi:10.1203/pdr.0b013e3181c1b176 · Cited by 782
Microenvironmental regulation of therapeutic response in cancer
Klemm, F., & Joyce, J. A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.006 · Cited by 771
Targeting the tumour vasculature: insights from physiological angiogenesis
Chung, A. S., Lee, J., & Ferrara, N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2868 · Cited by 752
Transport of drugs from blood vessels to tumour tissue
Dewhirst, M. W., & Secomb, T. W. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.93 · Cited by 749
Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF)
Byrne, A. M., Bouchier-Hayes, D. J., & Harmey, J. H. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00379.x · Cited by 744
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
“Preclinical studies showed that suppression of VEGF signalling can lead to improvements in tumour vessel function (vascular normalisation), and in turn, this was proposed to mediate increased delivery of chemotherapy to tumours [71, 72].”
BackgroundSurvival of the Fittest: Cancer Stem Cells in Therapeutic Resistance and Angiogenesis
Eyler, C. E., & Rich, J. N. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.1829 · Cited by 737
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis
Lohela, M., Bry, M., Tammela, T., & Alitalo, K. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.012 · Cited by 738
Wiig, H., & Swartz, M. A. (2012) · Physiological Reviews · doi:10.1152/physrev.00037.2011 · Cited by 722
Murat, A., Migliavacca, E., Gorlia, T., Lambiv, W. L., Shay, T., Hamou, M.-F., de Tribolet, N., Regli, L., Wick, W., Kouwenhoven, M. C. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7164 · Cited by 721
“This is in accordance with the concept suggesting that antiangiogenic agents may temporarily lead to “normalization” of aberrant tumor vasculature, resulting in more efficient delivery of drugs and oxygen to the tumor.(39,40) In a recent trial, addition of the antiangiogenic integrininhibitor cilengitide appears to co…”
ResultDevelopmental and Pathological Angiogenesis
Chung, A. S., & Ferrara, N. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154002 · Cited by 722
Vakoc, B. J., Lanning, R. M., Tyrrell, J. A., Padera, T. P., Bartlett, L. A., Stylianopoulos, T., Munn, L. L., Tearney, G. J., Fukumura, D., Jain, R. K., et al. (2009) · Nature Medicine · doi:10.1038/nm.1971 · Cited by 719
“to the study of solid tumor biology in vivo has elucidated pathways and mechanisms of cancer progression and has led to new therapeutic strategie”
BackgroundSelf-citation
Metadata
- Authors
- Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Science
- Published
- 2005-01-07
- Volume
- 307
- Issue
- 5706
- Pages
- 58-62
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2006202974
- Cited by
- 5,527
- References
- 56
- Citations by year
- 2026: 245 · 2025: 212 · 2024: 202 · 2023: 220 · 2022: 236 · 2021: 279 · 2020: 245 · 2019: 236 · 2018: 219 · 2017: 236 · 2016: 252 · 2015: 292 · 2014: 307 · 2013: 361 · 2012: 350
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- tumor vasculature normalization, anti-angiogenic therapy, tumor hypoxia, tumor oxygenation, drug delivery to tumors, combination cancer therapy, regenerative medicine, vascular function
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Cell Hypoxia, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.